SLGL
8:30 AM
Sol-Gel Reports Second Quarter 2026 Financial Results and Provides Corporate Updates
Pivotal Phase 3 clinical trial of SGT-610 (patidegib gel, 2%) for Gorlin syndrome remains ongoing, with top-line results on track for anticipated readout in late November 2026 Sol-Gel has initiated a proof-of-concept study in High-frequency BCC (HF-BCC) Sol-Gel initiated a study evaluating topical
sol-gel.com